2 Outstanding Dividend Stocks to Buy and Hold for a Decade

Eli Lilly reported Q2 revenue growth of 48% year over year to $23.0 billion and adjusted EPS growth of 33% to $8.38, supported by Mounjaro and Zepbound; its dividend has more than doubled over five years despite a modest 0.6% forward yield. Merck posted Q2 sales of $16.6 billion, up 5%, while facing Keytruda's U.S. patent-expiry risk in 2028; management's growth offsets include subcutaneous Keytruda Qlex, Winrevair, Capvaxive, and pipeline assets. Merck's forward dividend yield is 2.3%, with payouts up nearly 90% over the past decade.

Analysis

LLY remains a quality-growth compounder, but the relevant debate is no longer demand visibility; it is duration of excess returns versus a premium valuation. Incremental upside over the next 1-3 months requires evidence that supply expansion converts untreated demand into net-new volume rather than lower persistence, greater rebating, or channel inventory. The more important 6-18 month differentiator is whether Lilly can sustain superior efficacy/tolerability across successive incretin generations, preserving pricing power as Novo Nordisk (NVO), Amgen (AMGN), Pfizer (PFE), and oral GLP-1 entrants broaden choice.

MRK is a different setup: the market should value it as a patent-cliff execution story, not a dividend story. Its rerating hinges on the proportion of the oncology franchise retained through formulation switching, contracting behavior, and physician adoption before biosimilar competition changes economics. Subcutaneous convenience may protect utilization but does not necessarily protect net price; payor formulary decisions and biosimilar discount depth are the key variables. Winrevair uptake, vaccine launch execution, and business-development activity must collectively close a large future earnings gap to prevent multiple compression over 2027-29.

The contrarian view is that LLY's near-term operational success can still produce a weak stock return if consensus estimates and terminal assumptions already embed prolonged category dominance. Conversely, MRK's low-growth framing may understate its optionality if conversion and launch metrics beat conservative expectations, but that is an earnings-revision trade rather than a yield trade. NFLX and NVDA are editorially referenced only; there is no investable read-through to either ticker.

Key Decisions for Investors

• Maintain LLY as a core long only on pullbacks or after independently verified prescription/realized-price data confirm demand is exceeding expanded supply; use a 6-18 month horizon. Risk/reward is unfavorable if forward revenue estimates rise while gross-margin guidance fails to follow—reduce exposure on that divergence.
• Establish a 3-6 month relative-value watch: long MRK / short a matched beta basket of large-cap pharma (for example, PFE) only if quarterly Winrevair demand and Keytruda subcutaneous conversion exceed management’s disclosed launch milestones. Falsify if net pricing deteriorates or conversion stalls despite broad access.
• For existing LLY exposure, prefer defined-risk downside hedges around earnings and major clinical/regulatory events, such as 3-6 month put spreads financed partially with out-of-the-money calls. The key risk is a valuation reset from slower prescription growth rather than an outright collapse in category demand.
• Do not add to MRK solely for dividend yield. Reassess position sizing after each earnings release against three indicators: oncology net sales trajectory, new-product contribution, and 2028-plus revenue bridge; absence of upward guidance revisions over the next 2-3 quarters argues for neutral weight.